← SynDRA
LEVETIRACETAM
SynDRA canonical compound SYN0005031 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | SV2A |
|---|
| Mechanism of action | Calcium channel blocker |
|---|
| Indication | seizures |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- SV2A
- CACNA1B
- SCN1A
- CA1
- CACNA1G
- HTR3A
- Sv2a
Mechanisms of action (all sources)
- Calcium channel blocker
- SV2A MODULATOR
- Synaptic vesicle glycoprotein 2A modulator
- CACNA1B BLOCKER
- Voltage-gated N-type calcium channel alpha-1B subunit blocker
- HTR3A ANTAGONIST
Drug classes
- Anticonvulsants
- Central Nervous System Agents
- Nootropic Agents
ATC classes
Cross-references
Synonyms
- keppra
- matever
- (-)-Levetiracetam
- levroxa
- UCB 6474
- Elepsia
- Levetiracetam accord
- Levetiracetam actavis
- Levetiracetam hospira
- Levetiracetam sun
- Levetiracetam teva
- Levetiracetame
- AGB-101
- N03AX14
- NSC-760119
- UCB-22059
- UCB-L059
- Desitrend
- Elepsia xr
- Keppra
- Keppra xr
- Levetiracetam actavis group
- Levetiracetam in sodium chloride
- Levetiracetam ratiopharm
- Matever
- Spritam
- (S)-2-(2-Oxopyrrolidin-1-yl)butanamide
- Keppra XR
- Levetiracetamum
- (2S)-2-(2-oxopyrrolidin-1-yl)butanamide
- UCB-L 059
- (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
- (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
- SIB-S1
- UNII-44YRR34555
- 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-
- Levetiracetamum [INN-Latin]
- Levetiractam
Reported adverse events
- Alopecia
- Amnesia
- Vertigo
- Infection
- Diplopia
- Cough
- Somnolence
- Asthenia
- Depression
- Agitation
- Constipation
- Dizziness
Look up LEVETIRACETAM in the interactive SynDRA portal →